- Home
- YSXT vs MAIA Comparison
YSXT vs MAIA Comparison
Compare YSXT & MAIA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | YSXT | MAIA |
|---|---|---|
| Founded | 2011 | 2018 |
| Country | China | United States |
| Employees | N/A | N/A |
| Industry | Automotive Aftermarket | Biotechnology: Pharmaceutical Preparations |
| Sector | Consumer Discretionary | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 58.6M | 44.9M |
| IPO Year | 2024 | 2022 |
Fundamental Metrics
Financial Performance| Metric | YSXT | MAIA |
|---|---|---|
| Price | $1.50 | $1.36 |
| Analyst Decision | | |
| Analyst Count | 0 | 0 |
| Target Price | N/A | N/A |
| AVG Volume (30 Days) | 866.0K | ★ 873.7K |
| Earning Date | 07-31-2025 | 11-07-2025 |
| Dividend Yield | N/A | N/A |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 0.18 | N/A |
| Revenue | ★ $71,452,736.00 | N/A |
| Revenue This Year | N/A | N/A |
| Revenue Next Year | N/A | N/A |
| P/E Ratio | $8.30 | ★ N/A |
| Revenue Growth | ★ 22.04 | N/A |
| 52 Week Low | $1.25 | $0.87 |
| 52 Week High | $9.96 | $2.74 |
Technical Indicators
Market Signals| Indicator | YSXT | MAIA |
|---|---|---|
| Relative Strength Index (RSI) | 30.97 | 56.22 |
| Support Level | $1.25 | $1.07 |
| Resistance Level | $2.45 | $1.25 |
| Average True Range (ATR) | 0.32 | 0.16 |
| MACD | -0.08 | 0.06 |
| Stochastic Oscillator | 20.83 | 54.41 |
Price Performance
Historical ComparisonAbout YSXT YSX Tech. Co. Ltd Class A Ordinary Shares
YSX Tech Co Ltd provide business solutions to enterprise customers, mainly insurance companies and brokerages, in China. The company has three operating segments: Auto Insurance Aftermarket Value-added Services, Other Scenario-based Customized Services and Software Development and Information Technology Services. Key revenue is generated from Auto Insurance Aftermarket Value-added Services segment which include four types value added services: vehicle safety inspection and check services, vehicle driving risk screening services, designated driver and rescue services and vehicle maintenance and other value-added services.
About MAIA MAIA Biotechnology Inc.
MAIA Biotechnology Inc is a clinical-stage biopharmaceutical company developing targeted immunotherapies for cancer. THIO (6-thio-dG or 6-thio-2 '-deoxyguanosine), its lead asset, is an investigational dual mechanism of action drug candidate incorporating telomere targeting and immunogenicity. Patients with advanced NSCLC will be treated first with THIO followed a few days later by the immune checkpoint inhibitor Libtayo (cemiplimab), manufactured and commercialized by Regeneron.